Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Norgine B.V.
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
Plus deals involving Zai Lab/MacroGenics, Ono/Rafael Pharmaceuticals, Beijing Podconley/Norgine, Nuance/Verona and BeiGene/Shoreline.
The mid-sized pharmaceutical company Norgine aims to grow its specialty business in Europe through targeted business development activities, while at the same time separating out its consumer healthcare activities into a new subsidiary.
Following a strategic review, AMAG goes to Covis. Vincera goes public in merger with blank check company, has pending cancer deal with Bayer.
- Drug Delivery
- Specialty Pharmaceuticals
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- Azanta A/S
- Merus Labs Inc.
- Norgine Healthcare B.V
- Norgine Ventures Management Limited
- SpineVision SA
- SpePharm A.G.